These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 18350446)

  • 21. Variability in hemoglobin levels: clinical implications. Case study of the anemic patient.
    Candela JM; Dutka P; Bennett J; Holland M; Donahue C; Delorme J; Lynn R
    Nephrol Nurs J; 2001 Oct; 28(5):567-70. PubMed ID: 12143433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of variability in anemia management on hemoglobin outcomes in ESRD.
    Lacson E; Ofsthun N; Lazarus JM
    Am J Kidney Dis; 2003 Jan; 41(1):111-24. PubMed ID: 12500228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
    Dukkipati R; Kalantar-Zadeh K
    Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients.
    Chan K; Moran J; Hlatky M; Lafayette R
    Nephrol Dial Transplant; 2009 Jun; 24(6):1956-62. PubMed ID: 19176685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents.
    Malovrh M; Hojs N; Premru V
    Artif Organs; 2011 Jan; 35(1):63-8. PubMed ID: 20618233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dialysis adequacy and Kidney Disease Outcomes Quality Initiative goals achievement in an Iranian hemodialysis population.
    Malekmakan L; Haghpanah S; Pakfetrat M; Malekmakan A; Alimanesh M; Haghpanah A; Khajedehi P
    Iran J Kidney Dis; 2010 Jan; 4(1):39-43. PubMed ID: 20081303
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N
    Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Iron deficiency is a common cause of bad response to epoetin treatment. It's important to follow iron status--not only the Hb value].
    Wallerstedt SM; Ljungman S; Broms E; Andrén L
    Lakartidningen; 2005 Sep 12-18; 102(37):2550-1, 2553-5. PubMed ID: 16200900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Managing anaemia in kidney transplant patients with chronic kidney disease].
    López Oliva MO; Del Castillo Caba D; Fernández Fresnedo G
    Nefrologia; 2009; 29 Suppl 1():25-30. PubMed ID: 19675658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triumph and tragedy: anemia management in chronic kidney disease.
    Novak JE; Szczech LA
    Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factor deficiency in the anemia of renal transplant patients with grade III-IV chronic kidney disease: baseline results of the ARES Study.
    Gentil MA; Pérez-Valdivia MA; López-Mendoza M; Ortega F; Arias M; Gómez-Alamillo C; Campistol JM;
    Transplant Proc; 2008 Nov; 40(9):2922-4. PubMed ID: 19010148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is it necessary to check outcomes to improve quality of care? The example of anemia management.
    Di Benedetto A; Richards N; Marcelli D; Basci A; Cesare S; Ponce P; Scatizzi L; Marotta P
    J Nephrol; 2008; 21 Suppl 13():S146-52. PubMed ID: 18446749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing anemia management in hospitalized patients with end-stage renal disease.
    Heung M; Mueller BA; Segal JH
    Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individualizing anaemia treatment: a discussion of case histories.
    Muirhead N
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi37-43. PubMed ID: 15958826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EPO adjustments in patients with elevated hemoglobin levels: provider practice patterns compared with recommended practice guidelines.
    Collins AJ; Ebben JP; Gilbertson DT
    Am J Kidney Dis; 2007 Jan; 49(1):135-42. PubMed ID: 17185154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing patterns of anemia management in US hemodialysis patients.
    Freburger JK; Ng LJ; Bradbury BD; Kshirsagar AV; Brookhart MA
    Am J Med; 2012 Sep; 125(9):906-14.e9. PubMed ID: 22938926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The optimal hemoglobin in dialysis patients- a critical review.
    Singh AK; Fishbane S
    Semin Dial; 2008; 21(1):1-6. PubMed ID: 18251947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Updating practices in an evolving IV iron and anemia environment: practical solutions.
    Amerling R; Easom A; Juergensen P
    Nephrol Nurs J; 2007; 34(5):533-41; quiz 542-3. PubMed ID: 18041456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.